CNS Pharmaceuticals. with ticker code (CNSP) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 7 calculating the mean target price we have 7.5. Now with the previous closing price of 1.84 this is indicating there is a potential upside of 307.6%. There is a 50 day moving average of 2.11 while the 200 day moving average is 1.99. The company has a market cap of $45m. Visit the company website at: http://www.cnspharma.com
CNS Pharmaceuticals., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals. was founded in 2017 and is based in Houston, Texas.